Valuation dashboard for CDT Equity Inc. (CDT) with P/E 0.00, P/B 0.01, EV/EBITDA 3.99 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clin...
Analysis Summary
Trailing-twelve-month margins: gross margin 38.7%, operating margin 11.6%, net margin 6.3%.
At the current price of $0.20, CDT trades at a P/E of 0.00 and an ROE of 9.26%. Market capitalisation stands at $0M.
Balance sheet quality for CDT: current ratio of 1.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 0.00 |
| Price / Book | 0.01 |
| EV / EBITDA | 3.99 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-1233.19 |
| vs Current Price | -622922.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CDT | CDT Equity Inc. | 0.00 | 0.01 | 9.3% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.20 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 9.26% |
| Return on Invested Capital | 4.47% |
| Return on Assets | 2.60% |
| Gross Margin | 38.65% |
| Operating Margin | 11.55% |
| Net Margin | 6.30% |
Related companies: CCM · COCH · ENVB · HEPA · LIXT · NIVF · PTPI
Explore sector: Healthcare · Biotechnology
More sections of CDT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks